Pahr Therapeutics Raises $14 Million Seed Financing to Pursue Innovative Treatments for Pulmonary Arterial Hypertension
Pahr Therapeutics, Inc. announced today that it has raised a $14M seed financing, led by RA Capital Management, AN Venture Partners and University of Tokyo Edge Capital Partners (UTEC). The company will use the proceeds to develop novel therapies for pulmonary arterial hypertension (PAH). In conjunction with this financing, RA Capital Management Partner Andrew Levin, MD/PhD, AN Venture Partners Managing Partner Ken Horne, and UTEC Partner and Board Director Atsushi Usami, PhD have joined the board of directors.
AN Venture Partners Announces Final Close of $200M Fund I
AN Venture Partners (ANV), a global biotech venture capital firm, today announced the final close of its first fund, AN Venture Partners I, LP, achieving its target of USD200 million (JPY29 billion), one of the largest Japan-focused biotech venture capital funds to date, and also one of the largest first-time biotech venture capital funds raised in the past year.
